Consistent Use of Lipid Lowering Therapy in HIV Infection Is Associated with Low Mortality

Henning J Drechsler (.hdrechsler@gmail.com)  
VA North Texas Health Care System  https://orcid.org/0000-0003-4026-9154

Colby Ayers  
University of Texas Southwestern Medical Center Medical School

James Cutrell  
University of Texas Southwestern Medical Center Medical School

Reuben Arasaratnam  
VA North Texas Health Care System; University of Texas Southwestern Medical Center

Roger Bedimo  
VA North Texas Health Care System; University of Texas Southwestern Medical Center Medical School

Research article

Keywords: HIV (PLWH), antihypertensives, serious infections

DOI: https://doi.org/10.21203/rs.3.rs-122948/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: In people living with HIV (PLWH), statins may be disproportionately effective but remain underutilized. A large prospective trial in patients with low to moderate cardiovascular (ASCVD) risk will reveal whether they should be considered in all PLWH. But its effect size may not apply to real-world PLWH with higher ASCVD and mortality risk. Also, the clinical role of non-statin lipid-lowering therapy (LLT) and LLT adherence in this population is unknown.

Methods: Comparative multi-level marginal structural model for all-cause mortality examining four time-updated exposure levels to LLT, antihypertensives, and aspirin in a virtual cohort of older PLWH. Incident coronary, cerebrovascular, and overall ASCVD events, serious infections, and new cancer diagnoses served as explanatory outcomes.

Results: In 23,276 HIV-infected US-veterans who were followed for a median of 5.2 years after virologic suppression overall mortality was 33/1,000 patient years: >3 times higher than in the US population. Use of antihypertensives or aspirin was associated with increased mortality. Past LLT use (>1 year ago) had no effect on mortality. LLT exposure in the past year was associated with a reduced hazard ratio (HR) of death: 0.59, 95% confidence interval (CI) 0.51-0.69, p<0.0001 for statin containing LLT and 0.71 (CI: 0.54-0.93), p=0.03 for statin-free LLT. For consistent LLT use (>11/12 past months) the HR of death was 0.48 (CI: 0.35-0.66) for statin-only LLT, 0.34 (CI: 0.23-0.52) for combination LLT, and 0.27 (CI: 0.15-0.48) for statin-free LLT (p<0.0001 for all). The ASCVD risk in these patients was reduced in similar fashion. Use of statin containing LLT was also associated with reduced infection and cancer risk. Multiple contrasting subgroup analyses yielded comparable results. Confounding is unlikely a major contributor to our findings.

Conclusions: In PLWH, ongoing LLT use may lead to substantially lower mortality, but consistent long-term adherence may be required to reduce ASCVD risk. Consistent non-statin LLT may be highly effective and should be studied prospectively.

Background

There is a persistent life expectancy gap of 89 years between people living with HIV (PLWH) and the general population [1, 2]. Reasons may include an increased risk for atherosclerotic cardio- and cerebrovascular disease (ASCVD) events [3, 4], non-AIDS defining cancers [5], osteoporosis, and accelerated liver fibrosis [6] which have been summarized as HIV-associated non-AIDS comorbidity and carry, along with non-AIDS-defining infections, a higher attributable mortality in PLWH [7, 8].

Hydroxymethylglutaryl Coenzyme A reductase inhibitors (statins) could potentially bridge this life expectancy gap as their use has been linked to a greater than 50% reduction in all-cause mortality in several cohort studies [9–11]. But statins have never been shown to reduce ASCVD events in PLWH and other analyses have either failed to show a statin-associated mortality benefit [11, 12] or found one comparable to the general population [13]. Also, large beneficial statin-attributed treatment effects in
some observational studies have been identified as the result of methodological flaws [14]. Given this uncertainty about the true extent of their benefit, statins remain substantially underutilized in PLWH [15] (based on the 2013 AHA/ACC Cholesterol treatment guidelines [16]).

The question whether all PLWH should receive statins may be answered by a large multinational trial of pitavastatin in PLWH aged 40–75 years with low to moderate ASCVD risk, scheduled to conclude by 2023 [17, 18]. But its effect size may not apply to real-world PLWH with higher cardiovascular and all-cause mortality risk for whom a placebo-controlled trial was not ethically or practically feasible. As these patients may already struggle with polypharmacy and poor antiretroviral therapy (ART) adherence, a clinician’s enthusiasm to promote statins will be best informed by an accurate estimate of their population-specific clinical benefit.

The US Veterans Affairs (VA) HIV Clinical Case Registry (CCR) was a racially diverse virtual cohort of all HIV-infected US-veterans until 2012, based on the VA’s electronic medical records, including its Pharmacy Benefits Management database [19]. VA-pharmacies are the exclusive source for prescription medications for most US veterans and require very low or no medication co-pays. Their detailed inpatient and outpatient prescription and refill records lend themselves to the creation of granular day-to-day medication exposure models. This allowed for a comprehensive analysis of clinical effectiveness of preventive medications.

Methods

Patients and Follow-Up

We included All HIV-infected US veterans who received care at VA centres from 1996–2011 and achieved an undetectable HIV viral load (VL) after starting highly active antiretroviral therapy (HAART). Follow-up began at the day of the first undetectable VL (undetectable at any level or quantified < 50 copies/mL) and ended at the earliest occurrence of: death, loss of clinical follow-up for > 13 months, or 1/1/2012 (end of available data). The VA North Texas Health Care System Institutional Review Board approved this study.

Outcomes

The primary outcome was all-cause mortality. Death dates in the CCR were recorded and updated locally and centrally reconciled with VA benefits databases. The sensitivity of this method has been estimated between 9197% [20]. As cause of death was not available, we additionally examined acute ASCVD events (overall, coronary, or cerebrovascular), severe infections, and new cancer as explanatory outcomes. Infection and cancer outcomes were derived from the first relevant ICD-9 code during follow-up and excluded infection codes for cellulitis, upper respiratory infections, or cystitis and cancer codes for squamous and basal cell skin cancers. ASCVD-related ICD-9 codes were often administratively added – possibly to justify use of preventive cardiovascular medications. To minimize differential outcome misclassification, we excluded all ASCVD events without a well-defined day of onset by using an
algorithm based on ICD-9 and procedure codes, laboratory values, and neuroimaging dates (see Supplement 1.2).

Fig. S1, Tables S1-3).

**Medication Exposure**

We calculated 1-year “percent of days covered” (PDC) [21] for the following preventive drugs and drug classes: 1) Lipid Lowering Therapy (LLT): statin compounds, 2) non-statins (NS): fibrates, fish oil preparations, ezetemibe, and niacin; 3) Antihypertensives (AHT): angiotensin antagonists, beta blockers, calcium channel blockers, non-loop diuretics, and others; 4) cardiac aspirin (ASA) and also for all individual ARV agents. We used a day-to-day exposure model that accounted for hospitalizations, early refills, prescription of incompatible drug classes, and prescription of different drugs within the same class (Supplement 2). HAART adherence was defined as 1-year PDC of accepted combinations of ARVs (Supplement 2). All medication PDCs and HAART adherence were updated weekly and at the day of clinical event and binned into mutually exclusive time-updated exposure levels:

1) **consistent exposure**: exposed ≥ 11/12 past months (> 91% PDC), 2) **recent inconsistent exposure**: any exposure in the last year < 11/12 months, 3) **remote exposure**: prior use but not during the last year, and 4) **never exposed** (reference category).

Within the consistent exposure level, we differentiated between statin-only and statin-free LLT use - defined as either exclusive or no use of statins during the last year - and assigned all other exposures as combination LLT. For consistent AHT exposures, we distinguished between single and combination AHT. For recent and remote exposures, we distinguished between statin-containing and statin-free LLT. We also studied individual statin compounds and drug classes (NS-LLT, AHT) in a separate model of current exposure (supplement).

**Statistical Models**

We considered main effect and clinically relevant 2-way interactions for any parameter that potentially affected both outcome and likelihood of LLT, AHT, or ASA exposure in prediction models for each endpoint and all presented subgroup analyses. These Cox survival models included: individual ARV-PDCs, 1-year HAART adherence, HIV-specific and metabolic laboratory values, vital signs, and comorbidities. Comorbidity status was derived from ICD-9 or procedure codes and/or laboratory values. PDCs and laboratory covariates were calculated from time-weighted, weekly updated running averages over the past year. TDF was the only individual ARV component independently associated with decreased mortality in the predictor models (Table S7). All significant (p < 0.05) terms from the predictor models and the categorized frequency of outpatient follow-up were introduced into generalized linear models to generate propensity scores for each exposure level of each preventive drug category and endpoint (Tables S6a/b). Each individual propensity score level was stabilized by its relative frequency and truncated at the 5th and 95th percentile (asymmetric truncation) to reduce unmeasured confounding [22]. The final, inverse probability weighted (IPW) survival models controlled for multi-level exposures to the three
preventive drug classes and also included a censoring weight (for mortality). We used the Benjamini Hochberg method for multiplicity correction of p-values for all analyses in the overall population [23].

**Computing and Software**

Data extraction, cleaning, compilation, medication PDCs, and generalized linear models were calculated with SPSS (Versions 23 to 25, IBM Corporation, Armonk, NY) and Microsoft Excel for Windows (Microsoft Corporation, Redmond, WA). The survival models for the predictor selection were calculated at the Texas Advanced Computing Center at the University of Texas in Austin using the survival package [24] of R, Version 3.4 (Foundation for Statistical Computing, Vienna, Austria). For the final survival models, we used the same package using R, Version 3.53.

**Results**

**Cohort Composition and Comorbidity**

We followed 23,267 patients for a median of 5.2 years, inter-quartile range (IQR): 2.5–9.2 years, which amounted to 140,130 patient years (Table 1, Table S8a). Sixty-six percent of follow-up time was spent during sustained (≥ 1 year) virologic suppression. Comorbidity rates at end of follow-up, were as follows: 56% nicotine use (ever), 27% prevalent ASCVD (baseline 14%), 26% Hepatitis C, 11% congestive heart failure, 10% peripheral vascular disease, 10% chronic kidney disease (estimated glomerular filtration rate < 60 ml/min), 9% liver fibrosis (aspartate aminotransferase-to-platelet ratio index ≥ 1.5), and 6% diabetes mellitus.

**Mortality and Censoring**

Twenty percent (n = 4,622) of the cohort died; 40% during hospitalizations at VA facilities. Mortality (33 deaths/1,000 patient years) was more than three times higher than for an age, gender, race, and time matched sample of the US-population [25] but improved over time, most pronounced after 2005 and in patients with sustained virologic suppression (Table S8b). Seventy-two percent of deaths occurred in patients with prevalent ASCVD or prior infection or cancer endpoint and 51% in patients without sustained virologic suppression. Sixteen percent of patients (n = 3,659) were prematurely censored for interruption of care of > 13 months or loss of clinical follow up before January 1st, 2012.

**Explanatory End Points**

Six percent (n = 1,304) of patients had an acute ASCVD event (896 acute coronary events, 466 acute cerebrovascular events, 58 with both), 28% (n = 6,618) a serious infection (9% AIDS defining, 21% other serious infection) and 15% (n = 3,469) a new cancer diagnosis.

**Extent, Interdependence, and Persistence of Drug Exposures**
Age specific exposure rates to HAART and LLT were correlated with each other and with virologic suppression and changed over time (Table S8b). Forty-two percent of patients ever took LLT (36% statins, 21% NS-LLT, 15% both), 63% AHT, and 35% cardiac aspirin. Consistent LLT users were co-exposed to AHT for 59% and to ASA for 19% of follow-up time. Persistence of exposure after initial prescription was as follows: 54% of follow-up time for statins, 45% for NS-LLT, 63% for AHT, and 30% for aspirin. The consistent exposure level was characterized by high cumulative drug exposures (median > 4 years, Table S5).

**Model Correctness and Covariate Balance**

Figure 1 shows the absolute standardized differences for each of the 25 covariates and interaction terms between consistent LLT users and patients without prior LLT exposure in the mortality model (Figure S4 for AHT/ASA) and illustrates that covariate balance was achieved [26]. The means of the inverse weights for each exposure level and for each endpoint were almost entirely between 0.9 and 1.1 (except for consistent aspirin use: IPW mean 0.85). We confirmed the proportional hazards assumption by Schoenfeld Residuals. The global impact of weighting and multi-level exposure adjustment is shown in Table S13.

**All-cause Mortality and Explanatory outcomes**

Table 2 shows hazard ratios (HR) for all-cause mortality and explanatory outcomes for the different drug exposure levels. Exposures to aspirin and antihypertensives (except consistent aspirin use) were associated with increased mortality and ASCVD events, most pronounced for recent inconsistent and least for remote use. Remote LLT use had no impact on mortality. The observed mortality risk reduction for patients with recent inconsistent LLT exposures was 41% for statin-containing, and 29% for statin-free LLT. Consistent LLT use was associated with a mortality benefit of 52% for statin-only LLT, 66% for combination-LLT, and 73% for statin-free LLT. Only consistent LLT exposures were associated with a reduced risk for acute ASCVD events but a reduced risk for immunologic outcomes was seen for all statin exposures, including recent (infections) or remote use (cancer).

**Subgroup Analyses**

Table 3 displays the HR for all-cause mortality in contrasting subgroups of patients. The impact of consistent LLT exposure on mortality reduction was most pronounced for patients with incomplete viral suppression and those not receiving tenofovir disoproxil fumarate (TDF) as part of their HAART regimen but was attenuated for TDF users. Consistent use of combination LLT was associated with significantly reduced mortality in almost all examined subgroups which included patients on both sides of the ASCVD risk spectrum. We saw similar mortality risk reductions for patients with high HAART adherence, high use rates of contemporary HAART, or enrolment after 2006 (begin of the single-tablet regimen HAART era), particularly for statin-free and combination LLT (Table S13).

**Additional Analyses**
We analysed individual compounds and drug classes in separate models of ongoing use (≥ 3/4 past weeks), using remotely or never exposed patients as reference. All LLT components but none of the five AHT classes or aspirin were associated with increased survival which was significant for pravastatin, simvastatin, atorvastatin, fibrates, and niacin (Table S9a/b). Figure 2 shows the impact of ongoing current exposure to different LLT exposure levels on all-cause mortality after weighting, stratified by ASCVD status.

We explored the role of immortal time bias by replacing the requirement for 11 months of prior exposure in the consistent use level with > 91.5% use after treatment initiation during the first year and saw virtually identical results. The same also applied when we restricted the analysis to the new LLT users (84% started after enrolment).

We also investigated the impact of absolute serum low-density lipoprotein cholesterol (LDL) levels reached during follow-up in multivariable regression models which adjusted for AHT and ASA use and age. Within the same LLT exposure levels the HR for mortality and explanatory outcomes were similar across a wide array of LDL strata (Table S11). Also, there was no significant interaction between average serum LDL levels and long-term LLT use and mortality reduction.

**Discussion**

Prior HIV cohort analyses have reported a disproportionately large statin-associated mortality benefit of > 50% [9–11] which resembles reports of ≥ 40% reduced mortality among statin users in other populations with altered immunity [27–29], inherently increased (cardiovascular) mortality risk [30–33], or old age (25% mortality reduction in men > 75 years) [34]. Decreased mortality had never been observed in primary NS-LLT prevention trials but has recently been reported when icosapent-ethyl (fish oil component) or alirocumab (PSK-9 inhibitor) was added to statins in high-risk populations [35, 36].

The relationship between density of longitudinal LLT exposure and clinical effectiveness is incompletely understood. It could hinge on magnitude of cumulative exposure, consistency of exposure, and recency of use. To capture optimal exposures, “consistent use” in our multi-level exposure model required both > 91% adherence for ≥ 1 year and use within 30 days. To our knowledge, LLT effectiveness has not been analysed this way in high-risk populations. Multi-level time-updated drug exposure models have been tested [37], can address frailty bias [22], and are not subject to immortal time bias [14, 38]; both of which are known to lead to inflated treatment effects [14, 22].

The lack of a mortality benefit for remote LLT use argues against healthy user bias [39] and the lack of any benefit for consistent antihypertensive or aspirin use against healthy adherer bias [40] as explanations for the apparent mortality benefit of ongoing LLT use. The magnitude of the mortality benefit during consistent statin-free LLT use was unexpected and contrasted sharply with only moderately reduced mortality risk for inconsistent use – for which no reduced ASCVD risk was observed. Increased intra-individual (visit-to-visit) serum cholesterol variability has recently been identified as an important ASCVD and mortality risk factor [41, 42]. Albeit not yet biologically understood, this
phenomenon could potentially offset beneficial LLT effects in patients with low adherence and may even play a role in randomized controlled trials of LLT.

For statins, the mortality difference between consistent and inconsistent use was much smaller. This may reflect their sustained immunomodulatory properties, as evidenced by reduced infection and cancer risk even for inconsistent, respectively remote users.

Our mortality model met consistency, positivity, and correctness of weight-generation criteria of marginal structural models [43]. Similar reductions for overall ASCVD risk during consistent statin-free LLT and coronary risk during consistent statin-only LLT provide biologic plausibility for the reduced mortality risk. Yet after IPW and multi-level adjustment, consistent use of antihypertensives and aspirin remained associated with increased mortality and other adverse outcomes which indicates residual indication bias. This “stubborn” residual bias [44] was directed against patients taking cardiovascular preventive medications and would have affected statins similarly. As statins are arguably the most important preventive cardiovascular drug class, this residual bias may explain why they appeared less effective than statin-free LLT in reducing mortality. Yet, the lack of a cerebrovascular effect during consistent statin only LLT use is also noteworthy.

The current HAART era is characterized by high adherence to single tablet regimens, sustained virologic suppression, and durable immune restoration. We included patients only after achieving virologic suppression but continued to follow them regardless of virologic failure to avoid informative censoring. We further approximated contemporary conditions in contrasting subgroup analyses and observed comparable results. Consistent combination LLT use remained associated with significantly reduced mortality in all examined subgroups including patients with sustained virologic suppression and immune reconstitution and patients with low ASCVD risk. A notable exception were patients taking TDF containing HAART for whom the mortality impact of consistent LLT was attenuated. TDF (but not tenofovir alafenamide fumarate [45]) has well documented lipid lowering properties [46] and was the only ARV component independently associated with reduced mortality. Importantly, it is no longer used in most modern single-tablet HAART regimens.

There was no apparent association between absolute serum LDL levels and clinical outcomes within the same LLT exposure levels. But if the decreasing mortality risk from remote to consistent LLT exposures is interpreted as “dose-response relationship”, our study would fulfil most of the Bradford-Hill criteria [47] for causal inference between LLT use and mortality risk in PLWH. The REPRIEVE trial [17, 18] will provide the ultimate guidance on statin use in PLWH. But as unmeasured or uncontrolled confounding is unlikely a major explanation for our findings, broad use of lipid lowering therapy in HIV-infected US-veterans in past decades, including those without virologic suppression, could have saved thousands of lives.

The major strengths of our study are its comprehensiveness, its detailed drug exposure models, and its statistical approach. Others include cohort size and diversity, length of follow-up, and the reliance on uniform data collection on exposures and outcomes across the entire US-VA system. Limitations include an extreme male predominance, the lack of differentiation between different daily doses and the absence
of cause of death. Its major limitation is the remote timeframe. But before the publication of the 2013 AHA/ACC Cholesterol guidelines [16], non-statin lipid lowering agents were commonly combined with or substituted for statins to target risk-specific cholesterol goals [48]. This allowed our comparative analysis of different forms of LLT.

**Conclusion**

Our results emphasize the importance of consistency of LLT exposure and strongly support guideline-conforming use of statins in PLWH [49]. Promotion of LLT adherence in PLWH is likely a high yield intervention which should be combined with regular monitoring of serum lipid levels. The utility of non-statin lipid lowering therapy in PLWH should be studied prospectively.

**Abbreviations**

PLWH
people living with HIV
ASCVD
atherosclerotic cardio- and cerebrovascular disease
LLT
lipid lowering therapy
CI
95% confidence interval
HR
hazard ratio
IQR
inter quartile range
statin
Hydroxymethylglutaryl Coenzyme A reductase inhibitor
AHA/ACC
American Heart Association/American College of Cardiology
ART
antiretroviral therapy
VA
United States Department of Veterans Affairs
CCR
VA HIV Clinical Case Registry
VL
HIV plasma viral load
HAART
highly active antiretroviral therapy
PDC
percentage of days covered
NS
non-statin (lipid lowering therapy)
AHT
antihypertensive(s)
ASA
cardiac aspirin
TDF
tenofovir disoproxil fumarate
PI
protease inhibitor,
EFV
efavirenz
INSTI
raltegravir or elvitegravir.
LDL
low density lipoprotein cholesterol
PCE
pooled cohort equation to calculate 10 year ASCVD risk
Dx
diagnosis
avg
average
BMI
body mass index
eGFR
estimated glomerular filtration rate
BP
blood pressure (mmHg)
HCV
Hepatitis C
CHF
congestive heart failure
DM
diabetes mellitus
CVD
cardio- or cerebrovascular disease
HDL
high density lipo-protein cholesterol (mg/dL)
TC
total cholesterol (mg/dL)

OP
outpatient

freq
frequency

Declarations

- The VA North Texas Health Care System Institutional Review Board approved this study. Consent was waived because of minimal risk to participants and the nature of the study (de-identified data).
- Consent for publication: N/A
- The datasets used and/or analysed during the current study are available from the corresponding author on request.
- Competing interests: The authors declare no competing interests
- Funding: unfunded
- All authors have read and approved the manuscript. Individual contributions:
  - HD: study design, statistical analysis, manuscript preparation
  - CA: study design, statistical analysis
  - JC: study design, manuscript preparation
  - RA: manuscript preparation
  - RB: study design, manuscript preparation

Acknowledgements: The authors acknowledge the Texas Advanced Computing Center (TACC) at The University of Texas at Austin (http://www.tacc.utexas.edu) for providing high performance computing resources that have contributed to the research results reported within this paper. We also would like to thank all the staff of the Dallas VA ID section for their support, particularly our two long time physician assistants, Diana Turner and Teresa Moore. We also like to thank the members of the former Veteran’s Affairs Center for Quality Management in Public Health in Palo Alto, CA for compilation and dissemination of the CCR data.

Parts of this study were presented at the 25th Conference for Retroviruses and Opportunistic Infections 2019 in Seattle WA, USA, and the 17th European AIDS Conference 2019 in Basel, Switzerland.

References

1. Legarth RA, Ahlström MG, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Mohey R, Gerstoft J, Obel N. Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016;71(2):213–8.
2. Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, Hu H, Lam JO, Towner WJ, Yuan Q, Horberg MA, et al: Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000–2016. JAMA Network Open 2020, 3(6):e207954-e207954.

3. Strategies for Management of Antiretroviral Therapy Study G. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, et al: CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283–96.

4. Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Internal Medicine. 2013;173(8):614–22.

5. Bedimo RJ, Park LS, Shebl F, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, et al. Statin exposure and risk of cancer in people with and without HIV infection. Aids. 2020;11:11.

6. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.

7. Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, Burns F, Copas A, Brown AE, Sullivan AK, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. The Lancet Public Health. 2017;2(1):e35–46.

8. Goehringer F, Bonnet F, Salmon D, Cacoub P, Paye A, Chene G, Morlat P, May T. Causes of Death in HIV-Infected Individuals with Immunovirologic Success in a National Prospective Survey. AIDS Research Human Retroviruses. 2017;33(2):187–93.

9. Knobel H, Fratchez V, Montero M: The use of statins was associated with reduced mortality in HIV-infected patients [Abstract PE12/7]. In: 14th European AIDS Conference October 16–19. Brussels, Belgium; 2013.

10. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843.

11. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56(10):1471–9.

12. Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins. AIDS Patient Care Stds. 2015;29(6):307–13.

13. Uthman OA, Nduka C, Watson SI, Mills EJ, Kengne AP, Jaffar SS, Clarke A, Moradi T, Ekstrom AM, Lilford R. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):258.

14. Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601–6.
15. Kelly SG, Krueger KM, Grant JL, Penugonda S, Feinstein MJ, Taiwo BO, Achenbach CJ. Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2017;76(1):e26–9.

16. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129(25_suppl_2):49–73.

17. Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019;212:23–35.

18. Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. J Infect Dis. 2020;222(Supplement_1):1–7.

19. Backus L, Mole L, Chang S, Deyton L. The Immunology Case Registry. J Clin Epidemiol. 2001;54(Suppl 1):12–5.

20. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462–8.

21. Arnet I, Kooij MJ, Messerli M, Hersberger KE, Heerdink ER, Bouvy M. Proposal of Standardization to Assess Adherence With Medication Records: Methodology Matters. Ann Pharmacother. 2016;50(5):360–8.

22. Stürmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology. 2019;59(1):14–25.

23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B. 1995;57(1):289–300.

24. Therneau T. A Package for Survival Analysis in S_ version 2.38. In.: http://CRAN.R-project.org/package=survival; 2015.

25. Detailed Tables for the National Vital Statistics Report (NVSR) "Deaths: Final Data for 2013 http://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm.

26. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in medicine. 2015;34(28):3661–79.

27. Cheng CY, Kung CT, Chen FC, Cheng HH, Tsai TC, Hsiao SY, Su CM. Impact of prior statin use on mortality in patients with type 2 diabetes mellitus and bloodstream infection. J Int Med Res. 2019;47(8):3636–47.

28. Oza A, Lu N, Schoenfeld SR, Fisher MC, Dubreuil M, Rai SK, Zhang Y, Choi HK. Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis. 2017;76(10):1737–42.

29. Patel SS, Rodriguez VA, Siddiqui MB, Faridnia M, Lin F-P, Chandrakumaran A, Laurenzano J, Clinton J, Kowlgi GN, Kirkman D, et al. The Impact of Coronary Artery Disease and Statins on Survival After
30. An K, Huang R, Tian S, Guo D, Wang J, Lin H, Wang S: **Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis.** *Lipids in Health & Disease* 2019, **18**(1):N.PAG-N.PAG.

31. Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scaglia Rini S, Carteni G, Federico P, Daniele B, et al. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. *European Urology Focus*. 2018;4(6):874–9.

32. Lin HC, Tsai WC, Lin JR, Chang WN, Huang CC, Wang HC, Kung CT, Su CM, Su YJ, Lin WC, et al. Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: A population-based epidemiological study from Taiwan. *Journal of Clinical Neuroscience*. 2019;69:224–9.

33. Rusnak J, Behnes M, Schupp T, Lang S, Reiser L, Tatog A, Reichelt T, Egguth D, Engelke N, et al: **Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias.** *Lipids in Health & Disease* 2019, **18**(1):N.PAG-N.PAG.

34. Orkaby AR, Driver JA, Ho Y-L, Lu B, Costa L, Honerlaw J, Galloway A, Vassy JL, Forman DE, Gaziano JM, et al. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. *Jama*. 2020;324(1):68–78.

35. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med*. 2018;380(1):11–22.

36. Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. *Circulation*. 2019;140(2):103–12.

37. Eber M, Platt RW, Reynier P, Filion KB. Estimation of high-dimensional propensity scores with multiple exposure levels. *Pharmacoepidemiol Drug Saf*. 2020;29(Suppl 1):53–60.

38. Suissa S. Immortal time bias in pharmaco-epidemiology. *Am J Epidemiol*. 2008;167(4):492–9.

39. Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, Cadarette SM, Mogun H, Brookhart MA. The Association between Statin use and Outcomes Potentially Attributable to an Unhealthy Lifestyle in Older Adults. *Value in Health*. 2011;14(4):513–20.

40. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. *Circulation*. 2009;119(15):2051–7.

41. Simpson WG. Biomarker variability and cardiovascular disease residual risk. *Curr Opin Cardiol*. 2019;34(4):413–7.

42. Kim MK, Han K, Kim H-S, Park Y-M, Kwon H-S, Yoon K-H, Lee S-H. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. *Eur Heart J*. 2017;38(48):3560–6.

43. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology (Cambridge Mass)*. 2000;11(5):550–60.
44. Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64–74.

45. Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387–91.

46. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781–4.

47. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58:295–300.

48. Expert Panel on Detection E. Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486–97.

49. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019;140(2):e98–124.

Tables

Table 1: Demographics, Preventive medication experience and HAART effectiveness in three different time periods. Abbreviations: IQR: inter-quartile range, VL: HIV viral load, PI: protease inhibitor, TDF: tenofovir, EFV: efavirenz, INSTI: raltegravir or elvitegravir.
### Baseline characteristics over time (Median (IQR) or %)

|                          | 1996-2000 | 2001-2005 | 2006-2011 | Overall |
|--------------------------|-----------|-----------|-----------|---------|
|                          | n=7,434   | n=7,855   | n=7,987   | n=23,276|
| **Age**                  | 50 (44-56)| 53 (47-60)| 56 (48-64)| 53 (46-60)|
| **Female**               | 1.9%      | 2.4%      | 3.3%      | 2.5%     |
| **Race:**                |           |           |           |          |
| African American         | 38%       | 48%       | 53%       | 46%      |
| White                    | 34%       | 39%       | 37%       | 37%      |
| Unknown                  | 27%       | 12%       | 8%        | 15%      |
| **Smoking**              | 52%       | 59%       | 57%       | 56%      |
| **HCV co-infection**     | 34%       | 27%       | 19%       | 26%      |
| **CD4 (/mm³)**           | 312 (170-486) | 312 (176-484) | 355 (220-512) | 328 (189-496) |
| **VL LOG before HAART**  | 4.2 (3.3-4.9) | 4.6 (3.5-5.2) | 4.5 (3.5-5.0) | 4.4 (3.4-5.0) |
| **Years HIV Diagnosis-VL suppression** | 2.9 (0.9-5.3) | 3.4 (0.9-7.4) | 2.9 (0.8-7.9) | 3.0 (0.9-6.6) |
| **Prior preventive drug exposure:** | | | | |
| LLT                      | 2%        | 9%        | 12%       | 8%       |
| AHT                      | 17%       | 25%       | 30%       | 24%      |
| ASA                      | 4%        | 6%        | 6%        | 5%       |
| **Initial HAART:**       |           |           |           |          |
| None                     | 7%        | 12%       | 4%        | 8%       |
| Unboosted PI, no TDF    | 76%       | 19%       | 3%        | 32%      |
| Unboosted PI with TDF   | 0%        | 3%        | 2%        | 2%       |
| Boosted PI, no TDF      | 5%        | 17%       | 13%       | 12%      |
| Boosted PI with TDF     | 0%        | 11%       | 25%       | 12%      |
| EFV or INSTI, no TDF    | 12%       | 29%       | 12%       | 18%      |
| EFV or INSTI with TDF   | 0%        | 9%        | 41%       | 17%      |
| **One-year HAART adherence (Median)** | 65% | 74% | 84% | 79% |
| **One-year virologic suppression (Mean)** | 75% | 70% | 83% | 78% |

Table 2: All-cause mortality with explanatory endpoints. Top row of each cell shows hazard ratio (95% confidence interval), bottom row p-value followed by [number of events]. Cells with significant beneficial associations are framed. P-values are multiplicity corrected (Benjamini-Hochberg).
Table 3: Subgroup analyses. Criteria refer to preceding year. Top row of each cell shows hazard ratio (95% confidence interval), bottom row shows p-value followed by [deaths/patient years]. Cells with significant beneficial associations (no multiplicity correction) are framed. Abbreviations: TDF Use: Tenofovir Diproxyfumarate use for patients enrolled ≥ 2001. LDL chol: Low Density Lipoprotein Cholesterol. Low ASCVD risk: no known ASCVD and 10-year PCE risk score <10%, and native LDL cholesterol <4.1 mmol/L. High ASCVD risk: either known ASCVD, 10-year PCE risk score ≥ 10%, or native LDL cholesterol ≥ 4.1 mmol/L.
| Exposure >1 year | All-Cause Mortality | Incomplete viral suppression | Viral suppression & CD4>500/mm³ | TDF use | No TDF use | Low ASCVD risk | High ASCVD risk & viral suppression |
|------------------|---------------------|-------------------------------|----------------------------------|--------|------------|---------------|-----------------------------------|
| Mortality %      | [3,632/47,806]      | 4.9%                          | [601/42,662]                     | 1.4%   | [1,176/43,308] | [1,085/31,200] | [1,306/54,259] | [1,703/51,659] |
| LLT with Statin  | 1.10 (0.76-1.59)    | p=0.02 (35/7,244)             | 1.40 (0.90-2.18)                 | 1.22 (0.83-1.78) | 1.08 (0.70-1.67) | 1.14 (0.89-1.45) |
| LLT without Statin| 0.75 (0.52-1.09)   | p=0.24 (39/19,378)            | 0.98 (0.57-1.67)                 | 1.15 (0.64-1.87) | 0.88 (0.44-1.78) | 1.25 (0.84-1.87) |
| Any AHT          | 0.93 (0.45-1.62)    | p=0.03 (27/9,785)             | 0.93 (0.27-398)                  | 0.15 (24/42) | 0.73 (15/1,01) | 0.27 (49/1,171) |
| Cardiac Aspirin  | 1.04 (0.36-1.25)    | p=0.66 (249/5,640)            | 1.40 (1.04-1.88)                 | 1.28 (0.94-1.74) | 1.55 (1.16-1.93) | 1.34 (1.03-1.74) |
| Any AHT          | 0.84 (0.37-1.92)    | p=0.93 (343/5,440)            | 0.79 (0.49-1.35)                 | 0.69 (0.40-1.16) | 1.16 (0.83-1.62) | 1.05 (0.88-1.24) |
| Cardiac Aspirin  | 0.97 (0.40-1.65)    | p=0.001 (253/5,072)           | 0.89 (0.56-1.43)                 | 0.73 (0.39-1.34) | 0.98 (0.50-0.98) | 0.40 (0.26-0.57) |
| LLT with Statin  | 0.76 (0.54-1.05)    | p=0.001 (165/5358)            | 0.81 (0.63-1.04)                 | 0.48 (0.30-0.77) | 0.89 (0.75-1.05) |
| LLT without Statin| 0.92 (0.52-1.65)   | p=0.39 (77/1,872)             | 0.62 (0.40-1.05)                 | 0.69 (0.44-1.10) | 0.70 (0.50-0.98) |
| Cardiac Aspirin  | 2.56 (1.97-2.47)    | p=0.001 (1263/11,107)         | 2.37 (1.92-2.92)                 | 2.05 (1.65-2.55) | 3.12 (2.69-3.61) | 2.10 (1.73-2.55) |
| Any AHT          | 1.62 (1.36-1.92)    | p=0.001 (535/5,116)           | 1.55 (1.22-1.98)                 | 1.83 (1.43-2.34) | 1.92 (1.42-2.59) | 1.81 (1.56-2.11) |
| Cardiac Aspirin  | 0.84 (0.57-1.25)    | p=0.39 (77/1,872)             | 0.82 (0.49-1.35)                 | 0.69 (0.44-1.10) | 0.70 (0.50-0.98) |
| LLT with Statin  | 0.79 (0.50-1.10)    | p=0.001 (165/5358)            | 0.81 (0.63-1.04)                 | 0.48 (0.30-0.77) | 0.89 (0.75-1.05) |
| LLT without Statin| 0.57 (0.42-0.88)   | p=0.001 (41/1,366)            | 0.46 (0.24-0.88)                 | 0.44 (0.26-0.75) | 0.69 (0.44-1.10) | 0.70 (0.50-0.98) |
| Cardiac Aspirin  | 0.97 (0.40-1.65)    | p=0.001 (253/5,072)           | 0.89 (0.56-1.43)                 | 0.73 (0.39-1.34) | 0.98 (0.50-0.98) |
| Cardiac Aspirin  | 0.97 (0.40-1.65)    | p=0.001 (253/5,072)           | 0.89 (0.56-1.43)                 | 0.73 (0.39-1.34) | 0.98 (0.50-0.98) |
| Exposed >91% last year | | | | | | | |